ArticleCancer immunology, immunotherapy : CII2021

First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity.

Peter Ruf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.